GLP-1 Medications for PCOS: What the Research Shows

GLP-1 medications such as semaglutide and tirzepatide can help women with PCOS who carry excess weight lose weight and improve insulin resistance, and in a 2023 study by Carmina and Longo, 80 percent of the women who responded to low-dose semaglutide regained normal menstrual cycles. The 2023 international PCOS guideline says GLP-1 receptor agonists “could be considered” alongside lifestyle changes for managing higher weight, although neither drug is FDA approved for PCOS itself. The evidence for fertility and ovulation is still early and mostly indirect, the medications are prescription only and need medical supervision, and they are not recommended during pregnancy or while actively trying to conceive.

Why GLP-1 medications came up in PCOS care

Polycystic ovary syndrome (PCOS) is closely tied to insulin resistance. Many women with PCOS produce more insulin than expected for their blood sugar, and that excess insulin appears to drive higher androgen levels, irregular ovulation, and difficulty losing weight. For a fuller picture of the syndrome, see our complete guide to PCOS and the detailed look at PCOS and insulin resistance.

GLP-1 receptor agonists were developed for type 2 diabetes and later for obesity. They mimic a gut hormone (glucagon-like peptide-1) that slows stomach emptying, reduces appetite, and improves how the body handles insulin and glucose. Because weight and insulin resistance sit near the center of PCOS, researchers and clinicians began asking whether these drugs could help. Prescribing data backs up the interest. One analysis found that semaglutide or tirzepatide use among women with PCOS rose from roughly 2.4 percent in 2021 to about 17.6 percent in 2025, a more than sevenfold increase.

PCOS is usually diagnosed with the Rotterdam criteria, which look for two of three features: irregular or absent ovulation, signs of high androgens such as acne or excess hair growth, and polycystic ovaries on ultrasound. Not every woman with PCOS has insulin resistance or higher weight, which is one reason GLP-1 medications suit some women with PCOS far better than others. Signs that insulin resistance may be part of the picture are covered in our piece on the signs of insulin resistance.

What the research actually shows

The strongest signal so far is for weight and metabolic markers. Smaller signals exist for menstrual regularity. The fertility question remains mostly unanswered in well-designed trials.

Weight loss

In a 2023 study, low-dose semaglutide (0.5 mg weekly) reduced body weight in nearly 80 percent of women with PCOS who had not responded to a prior lifestyle plan, alongside improvements in fasting glucose and insulin resistance. A 2024 randomized, controlled trial of semaglutide combined with metformin in overweight or obese women with PCOS reported an average weight loss of about 6 kg over the treatment period, with larger reductions in BMI and waist circumference than metformin alone.

The 2023 study, by Carmina and Longo at the University of Palermo and published in the Journal of Clinical Medicine, followed 27 women. Mean weight loss was 7.6 kg after three months, and the women who responded kept going to a mean loss of 11.5 kg at six months, with mean BMI falling from 34.4 to 29.4. The study was small and uncontrolled.

Insulin resistance

Across these studies, insulin resistance measured by HOMA-IR tended to improve. This is consistent with what GLP-1 medications do in people with diabetes and obesity, and it matters for PCOS because better insulin sensitivity can help lower androgen levels over time.

In the Carmina and Longo study, HOMA-IR and fasting insulin improved even in women who lost less than 5 percent of their body weight, and fasting glucose normalized in 80 percent of the women who started with impaired fasting glucose. That suggests part of the metabolic benefit does not depend on the scale moving.

Ovulation and menstrual cycles

Several trials found that more women regained regular menstrual cycles on semaglutide-based treatment than on metformin alone. Earlier work suggested that women who lost more than 10 percent of their body weight saw the clearest improvement in cycle regularity. The leading interpretation is that the benefit is indirect. Weight loss and better insulin sensitivity drive hormonal normalization, which in turn supports more regular ovulation. Direct effects of GLP-1 drugs on the ovary are not well established in humans.

Androgens, acne, and hair growth

Studies of GLP-1 medications in PCOS report modest and inconsistent changes in testosterone and in symptoms such as hirsutism and acne. Any improvement tends to track weight loss and lower insulin. Women whose main concern is excess hair or hormonal acne usually need targeted treatments as well, such as a combined oral contraceptive pill or an anti-androgen, which a clinician can weigh against pregnancy plans.

Tirzepatide specifically

Tirzepatide is a dual GLP-1 and GIP receptor agonist that tends to produce larger weight loss than semaglutide in obesity trials. Dedicated PCOS data for tirzepatide are still limited. Most of what we know is extrapolated from its general weight and metabolic effects rather than from PCOS-specific trials. If you are weighing the two, our comparison of semaglutide versus tirzepatide covers the differences in more detail.

How GLP-1 medications compare with other PCOS treatments

GLP-1 receptor agonists are one option among several, and each PCOS treatment targets a different part of the condition. Metformin, an insulin sensitizer, is recommended in the 2023 guideline for metabolic features in adults with higher weight. Letrozole is the first line medicine for inducing ovulation when pregnancy is the goal, and the combined oral contraceptive pill remains the usual first choice for irregular cycles and androgen symptoms.

Inositol is an option with limited evidence, covered in inositol for PCOS and our metformin versus inositol comparison, while the overview of PCOS treatment options puts every choice side by side.

How these medications are used

GLP-1 medications are prescription only and given as a weekly injection with a small pen. Treatment usually starts at a low dose and increases gradually over weeks to reduce stomach side effects. In PCOS specifically, they are sometimes added on top of metformin rather than replacing it, since the two work through different mechanisms.

The 2023 international PCOS guideline positions GLP-1 receptor agonists as something that “could be considered” for managing higher weight in adults with PCOS, always alongside lifestyle changes rather than instead of them. Any use should be decided with a clinician who knows your full history.

What is the usual semaglutide and tirzepatide dosing schedule?

The FDA labels set a slow climb in dose: semaglutide starts at 0.25 mg weekly and tirzepatide at 2.5 mg weekly, each for 4 weeks, as the tirzepatide prescribing information on DailyMed shows. PCOS studies have often used lower doses, such as 0.5 mg weekly semaglutide in the Carmina and Longo study.

Who prescribes GLP-1 medications for PCOS?

Endocrinologists, gynecologists (OB-GYNs), primary care physicians and obesity medicine specialists all prescribe GLP-1 medications. Reproductive endocrinologists become involved when fertility is a goal. A registered dietitian often supports the nutrition and protein side, which matters for protecting muscle during weight loss.

Who is a good candidate for a GLP-1 with PCOS?

The women most likely to benefit are adults with PCOS who have higher weight or clear insulin resistance and who are not planning a pregnancy in the near term. The guideline frames GLP-1 receptor agonists as an addition to lifestyle work, not a replacement for it. Women with PCOS at a lower weight, or whose main concerns are acne or hair growth, have weaker reasons to start one.

GLP-1 medications are a poor fit during pregnancy, breastfeeding or near-term conception plans, and a history of pancreatitis, gallbladder disease or an eating disorder calls for a careful conversation first.

Caveats, safety, and side effects

These are real medications with real trade-offs. They require medical supervision, and the points below are educational, not a substitute for advice from your own clinician.

• Common side effects. Nausea, vomiting, diarrhea, and constipation are the most frequent. They often ease over time but can return when the dose is raised.
• Contraindications. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in those with a history of pancreatitis.
• Muscle and lean mass. Any rapid weight loss can include some lean mass, not only fat. Adequate protein and resistance training help protect muscle. Our piece on GLP-1 and muscle loss goes deeper, and you can also review the broader list of semaglutide side effects.
• Weight regain. Weight often returns after stopping, so these are usually framed as long-term tools rather than short courses.
• Pregnancy and conception. GLP-1 medications are not recommended in pregnancy. Guidelines advise effective contraception during use because pregnancy safety data are lacking, and a washout period of at least two months before trying to conceive is commonly recommended. This is especially relevant in PCOS, where restored ovulation can make pregnancy more likely than a woman expects.
• Birth control pills and tirzepatide. Tirzepatide can make birth control pills less effective. The prescribing information advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Many women with PCOS take the pill, so this deserves a direct question to the prescriber.
• Long-term safety. Long-term data in PCOS specifically are still limited, and most evidence is borrowed from diabetes and obesity populations.

Cost, insurance, and compounded GLP-1 medications

Insurance coverage for GLP-1 medications in PCOS is uneven because PCOS is not an FDA approved indication for semaglutide or tirzepatide. Coverage usually depends on a separate qualifying diagnosis, such as type 2 diabetes or obesity, and on the specific plan. Many women pay cash, so ask about prior authorization before starting. Price ranges are covered in our article on what semaglutide costs.

Some clinics and telehealth services offer compounded semaglutide or compounded tirzepatide. According to the FDA’s page on unapproved GLP-1 drugs, compounded versions are not FDA approved, are not reviewed for safety, effectiveness or quality before marketing, and have been linked to dosing errors. Our guides to compounded semaglutide and compounded tirzepatide explain what to ask about the pharmacy and the dose.

Finding a clinician who prescribes GLP-1 medications for PCOS

A good first step is the clinician who already manages your PCOS, since they know your cycle history, labs and pregnancy plans. Women who want a medically supervised weight or metabolic program outside that setting can look through clinics in our directory. Regenerated.com has no separate GLP-1 category, so start with the clinics that offer peptide therapy and the hormone therapy clinic directory, then confirm on each profile or by phone whether the clinic prescribes GLP-1 medications and works with PCOS. The peptide therapy treatment guide explains how those programs are usually run.

Listing order on Regenerated.com is not paid ranking, Featured slots are labeled and capped, Verified means the clinic completed credential checks rather than paying for placement, and the directory is free for patients. Inclusion in the directory is not an endorsement. The guide to Featured, Verified and organic listings explains each label.

Where this leaves you

For many women with PCOS and excess weight, GLP-1 medications offer a genuinely useful option for weight and metabolic health, with a likely knock-on benefit for cycle regularity. The fertility story is hopeful but not yet proven in strong trials, and the safety guardrails around pregnancy are important. The sensible path is a conversation with a clinician who can weigh your goals, your history, and whether a GLP-1 fits alongside the basics of nutrition, movement, sleep, and any existing PCOS treatment.

In short, semaglutide and tirzepatide are supported by good evidence for weight loss and insulin resistance in PCOS, by early evidence for more regular cycles, and by very little direct evidence for fertility. They are off label for PCOS, they need a clear plan for contraception and conception, and they work best on top of lifestyle changes and existing PCOS care.

Frequently asked questions

Can GLP-1 medications cure PCOS?

No. PCOS is a lifelong condition, and GLP-1 medications do not make it go away. They can improve some of its drivers, such as excess weight and insulin resistance, which may in turn improve symptoms like irregular cycles. They manage the condition rather than reversing it, and symptoms often return if the underlying factors return, for example when weight comes back after stopping the medication.

Will a GLP-1 help me get pregnant if I have PCOS?

It might help indirectly by reducing weight and improving ovulation, but the medications themselves are not approved fertility treatments and are not recommended while trying to conceive. MedlinePlus advises stopping semaglutide 2 months before a planned pregnancy. For ovulation induction, the 2023 PCOS guideline names letrozole as the first line medicine, so fertility goals are best planned with your clinician or a reproductive endocrinologist.

Is semaglutide or tirzepatide better for PCOS?

There is no clear answer yet for PCOS specifically. Semaglutide has more PCOS study data, while tirzepatide tends to produce larger weight loss in general obesity trials but has very little PCOS-specific evidence so far. Tirzepatide also reduces the reliability of birth control pills around dose changes. The right choice depends on your health profile, your contraception, and your clinician’s judgment.

Do I still need metformin if I start a GLP-1?

Possibly. Some PCOS studies used GLP-1 medications added on top of metformin rather than as a replacement, because they work through different pathways, and a 2024 randomized trial found the combination produced more weight and waist loss than metformin alone. Metformin remains a guideline recommended option for metabolic features of PCOS. Whether to combine or switch is a decision for your prescriber.

How much weight do women with PCOS lose on semaglutide?

Results vary, but published studies report average losses between about 6 and 11.5 kg. In the 2023 Carmina and Longo study, women with obesity and PCOS on semaglutide 0.5 mg weekly lost a mean of 7.6 kg in three months, and those who responded reached 11.5 kg at six months. A 2024 randomized trial of semaglutide plus metformin reported about 6 kg. About one in five women in the 2023 study lost less than 5 percent.

Is semaglutide FDA approved for PCOS?

No. Neither semaglutide nor tirzepatide is FDA approved for PCOS. Both are approved for type 2 diabetes and for chronic weight management, so prescribing them for PCOS is off label and usually rests on a weight or blood sugar indication. That affects insurance coverage, and it is why the 2023 international guideline uses the cautious wording “could be considered” rather than a firm recommendation.

Related reading

• PCOS: the complete guide
• PCOS and insulin resistance
• Semaglutide vs tirzepatide compared
• GLP-1 medications and muscle loss
• Semaglutide side effects

This article is for education, not medical advice. GLP-1 medications are prescription only and require supervision by a qualified healthcare professional. Always discuss your individual situation, including any plans for pregnancy, with your own clinician before starting, stopping, or changing treatment.